NYSE:WAT - Waters Stock Price, Price Target & More

Waters trades on the New York Stock Exchange (NYSE) under the ticker symbol "WAT."

Waters declared that its board has authorized a share repurchase plan on Tuesday, April 24th 2018, which permits the company to repurchase $3,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to buy up to 18.2% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company's board believes its shares are undervalued.

Waters Co. (NYSE:WAT) issued its earnings results on Tuesday, April, 24th. The medical instruments supplier reported $1.59 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $1.55 by $0.04. The medical instruments supplier had revenue of $530.70 million for the quarter, compared to the consensus estimate of $534.17 million. Waters had a return on equity of 25.80% and a net margin of 1.14%. The business's revenue for the quarter was up 6.6% on a year-over-year basis. During the same quarter last year, the company earned $1.46 EPS. View Waters' Earnings History.

Waters is scheduled to release their next quarterly earnings announcement on Tuesday, July, 24th 2018. View Earnings Estimates for Waters.

Waters updated its FY18 earnings guidance on Tuesday, April, 24th. The company provided EPS guidance of $8.10-8.30 for the period, compared to the Thomson Reuters consensus estimate of $8.19.

16 analysts have issued 12 month price objectives for Waters' shares. Their predictions range from $180.00 to $230.00. On average, they expect Waters' stock price to reach $206.1429 in the next twelve months. This suggests a possible upside of 6.5% from the stock's current price. View Analyst Ratings for Waters.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Waters in the last year. There are currently 2 sell ratings, 9 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

Some companies that are related to Waters include Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Bio-Rad Laboratories, Inc. Class A Common Stock (BIO), Bio-Rad Laboratories, Inc. Class B (BIO.B), PerkinElmer (PKI), Integra Lifesciences (IART), Bruker (BRKR), Coherent (COHR), Horiba (HRIBF), Accelerate Diagnostics (AXDX), Pacific Biosciences of California (PACB), Quanterix (QTRX), Fluidigm (FLDM) and Harvard Bioscience (HBIO).

News headlines about WAT stock have been trending somewhat positive recently, Accern reports. Accern rates the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Waters earned a news impact score of 0.15 on Accern's scale. They also gave media coverage about the medical instruments supplier an impact score of 46.05 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Waters' stock is owned by a number of of retail and institutional investors. Top institutional investors include Fenimore Asset Management Inc. (0.37%), Bank of Montreal Can (0.11%), Copper Rock Capital Partners LLC (0.08%), Fjarde AP Fonden Fourth Swedish National Pension Fund (0.03%), State of Alaska Department of Revenue (0.02%) and Denali Advisors LLC (0.02%). Company insiders that own Waters stock include Arthur G Caputo, Christopher A Kuebler, David Terricciano, Elizabeth B Rae, Eugene G Cassis, Ian King, Joann A Reed, Laurie H MD Glimcher, Mark T Beaudouin, Michael C Harrington, Michael F Silveira, Michael J Berendt, Rohit Khanna, Terrence P Kelly, Thomas P Salice and William J Miller. View Institutional Ownership Trends for Waters.

WAT stock was sold by a variety of institutional investors in the last quarter, including NN Investment Partners Holdings N.V., State of Alaska Department of Revenue, Fenimore Asset Management Inc., Copper Rock Capital Partners LLC, Gateway Investment Advisers LLC and Raymond James Trust N.A.. Company insiders that have sold Waters company stock in the last year include Christopher A Kuebler, David Terricciano, Elizabeth B Rae, Eugene G Cassis, Joann A Reed, Mark T Beaudouin, Michael C Harrington, Michael F Silveira, Rohit Khanna, Terrence P Kelly, Thomas P Salice and William J Miller. View Insider Buying and Selling for Waters.

WAT stock was bought by a variety of institutional investors in the last quarter, including DnB Asset Management AS, Bank of Montreal Can, Denali Advisors LLC, Fjarde AP Fonden Fourth Swedish National Pension Fund, IFM Investors Pty Ltd, Pennsylvania Trust Co and Ledyard National Bank. View Insider Buying and Selling for Waters.

Shares of WAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of WAT stock can currently be purchased for approximately $193.50.

Waters has a market capitalization of $15.52 billion and generates $2.31 billion in revenue each year. The medical instruments supplier earns $20.31 million in net income (profit) each year or $7.49 on an earnings per share basis. Waters employs 7,000 workers across the globe.

Waters' mailing address is 34 MAPLE STREET, MILFORD MA, 01757. The medical instruments supplier can be reached via phone at 508-478-2000 or via email at [email protected]